LASP-1—a promising urine marker for detection of bladder cancer

2012 ◽  
Vol 9 (5) ◽  
pp. 240-240 ◽  
Author(s):  
Sarah Payton
Keyword(s):  
Bladder Cancer ◽  
Urine Marker

scholarly journals Alternating Cystoscopy with Bladder EpiCheck ® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model

2021 ◽  
pp. 1-9
Author(s):  
Yair Lotan ◽  
Georgios Gakis ◽  
Matteo Manfredi ◽  
Juan Morote ◽  
Hugh Mostafid ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Specificity ◽  
Cancer Surveillance ◽  
European Countries ◽  
Cost Comparison ◽  
Sensitivity Analyses ◽  
Low Grade ◽  
Intermediate Risk ◽  
Tree Model ◽  
Urine Marker

BACKGROUND: Bladder cancer surveillance is invasive, intensive and costly. Patients with low grade intermediate risk non-muscle invasive bladder cancer (NMIBC) are at high risk of recurrence. OBJECTIVE: The objective of this model is to compare the cost of a strategy to alternate surveillance with cystoscopy and a urine marker, Bladder EpiCheck, to standard surveillance. METHODS: A decision tree model was built using TreeAge Pro Healthcare to compare standard surveillance (Standard) with a modified surveillance incorporating Bladder EpiCheck. The model was based on 2 years of surveillance. Outcomes were obtained from literature. Costs were obtained from US and 9 European countries. Sensitivity analyses were performed. RESULTS: The efficacy of the model was equivalent in terms of recurrence for each arm with median recurrence rate of 22%. When setting marker price at 200 local currency, the marker arm was less expensive in the USA, Netherlands, Switzerland, Belgium, Italy, Austria and UK by 154€ to 329€ per patient, for a 2-year period. Cost was higher in France, Spain, and Germany by 33–103€. Cost parity was achieved with marker price between 148€ and $421. Marker cost and specificity have the greatest impact on the overall model cost. CONCLUSIONS: A strategy alternating the urine marker Bladder EpiCheck with cystoscopy in the surveillance of patients with low grade intermediate risk bladder cancer is cost equivalent in the US and European countries when the marker is priced 148€ –$421, as a result of the marker’s high specificity (86%). Prospective studies will be necessary to validate these findings.

Tumor-Derived Hyaluronidase: A Diagnostic Urine Marker for High-Grade Bladder Cancer

1998 ◽  
Vol 160 (2) ◽  
pp. 619-620 ◽  
Author(s):  
H.T. Pham ◽  
N.L. Block ◽  
V.B. Lokeshwar
Keyword(s):  
Bladder Cancer ◽  
High Grade ◽  
Urine Marker

SOLUBLE FAS IS A NEW SENSITIVE AND SPECIFIC URINE MARKER FOR BLADDER CANCER PRESENCE AND STAGING

2006 ◽  
Vol 5 (2) ◽  
pp. 253
Author(s):  
S. Shariat ◽  
R. Svatek ◽  
Y. Lotan ◽  
A. Sagalowsky ◽  
R. Casella
Keyword(s):  
Bladder Cancer ◽  
Urine Marker ◽  
Soluble Fas

scholarly journals Tumor M2-PK: A novel urine marker of bladder cancer

PLoS ONE ◽  
2019 ◽  
Vol 14 (6) ◽  
pp. e0218737 ◽  
Author(s):  
Weiya Liu ◽  
Benjamin L. Woolbright ◽  
Karim Pirani ◽  
Ryan Didde ◽  
Erika Abbott ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urine Marker

Sex and Racial Disparities in the Treatment and Outcomes of Muscle-invasive Bladder Cancer

Urology ◽  
2020 ◽  
Author(s):  
Jessica Marinaro ◽  
Alexander Zeymo ◽  
Jillian Egan ◽  
Filipe Carvalho ◽  
Ross Krasnow ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Racial Disparities ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

775: Cell Culture Proteome Identifies CXCL 1 as a Secreted Marker and Mediator for the Tumor Invasion of Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 260-260 ◽  
Author(s):  
Hiroaki Kawanishi ◽  
Yoshiyuki Matsui ◽  
Toshinari Yamasaki ◽  
Takeshi Takahashi ◽  
Hiroyuki Nishiyama ◽  
...  
Keyword(s):  
Cell Culture ◽  
Bladder Cancer ◽  
Tumor Invasion

774: Improvement of Anti-Angiogenic and Anti-Tumorigenic Efficacy of Thrombospondin-1 by PPAR┌ Ligands in Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 259-259
Author(s):  
Thomas Nelius ◽  
Hanua Huang ◽  
Stephanie Filleur ◽  
Steven C. Campbell ◽  
Werner de Riese ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Thrombospondin 1 ◽  
Ppar Ligands

769: Matrix Metalloproteinase Polymorphisms are associated with Bladder Cancer Invasiveness

2007 ◽  
Vol 177 (4S) ◽  
pp. 258-258
Author(s):  
A. Karim Kader ◽  
Jun Liu ◽  
Una Shao ◽  
Colin P.N. Dinney ◽  
Jie Lin ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Matrix Metalloproteinase ◽  
Cancer Invasiveness
Sign in / Sign up

Export Citation Format

Share Document